Feasibility of 18F-Fluciclovine PET/CT to Identify Brain Metastasis

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 10, 2024

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2026

Conditions
Brain Metastases
Interventions
DIAGNOSTIC_TEST

18F-Fluciclovine (Axumin) PET/CT

"PET/CT protocol:~All patients will be instructed to fast for 4 hr. prior to the scan. CT imaging of the head will be performed using GE Discovery MI Digital PET/CT (Boston, Massachusetts) prior to the injection of 18F-fluciclovine. While the patient is in a supine position on the PET table, 5 mCi (185 MBq) of 18F-fluciclovine will be administrated intravenously, followed by a saline flush. At the time of the injection, a continuous dynamic PET images lasting 60 min will be performed using 3D-dynamic and list-mode acquisition: 2.0 mm slice thickness, number of frames(f) x time in seconds(s) and minutes(m) of: 4f x 15s, 4f x 30s, 6f x 2m, 5f x 3m, and 6f x 5m. PET images at 0-5 (flow), 15-25 (early), 25-35 (mid), 45-60 min (delayed) post-injection will be reconstructed using Qclear 500 and OSEM iterative reconstruction with TOF (VPFX): 8 iterations, 5 subsets, 440 image matrix, 4 mm Gaussian filter, TOF. \[24, 27\]."

Trial Locations (1)

85719

RECRUITING

Arizona Cancer Center at UMC North/University Medical Center, Tucson

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Blue Earth Diagnostics

INDUSTRY

lead

University of Arizona

OTHER

NCT06055790 - Feasibility of 18F-Fluciclovine PET/CT to Identify Brain Metastasis | Biotech Hunter | Biotech Hunter